Herantis Pharma to Participate in the Upcoming Investor and Partnering Conference

Herantis Pharma Plc, Press Release, 8 March 2022 at 09:00 EET

Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that Antti Vuolanto, Chief Operating Officer, will hold a company presentation at:

Sachs 5th Annual Neuroscience Innovation Forum (Virtual)

The presentation will be held on March 22, 2022

1×1 meetings will be scheduled with the management team during March 21 – 25, 2022

The presentation will be available via a digital library, which is accessible to event participants only. Please contact the conference organizers, or send an email to ir@herantis.com, if you wish to schedule a meeting with Herantis.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying, CDNF-based therapies for Parkinson’s disease that aim to restore proteostasis, body’s natural neuronal protective mechanism. A failure in proteostasis results in pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated in the development of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease. CDNF is a protein that occurs naturally in the body. Its role is to protect neurons by balancing proteostasis, thereby preventing and counteracting disease generating mechanisms.

Herantis' development focus is on the CDNF-based; HER-096 (a synthetic peptide). HER-096 has demonstrated to have a multimodal mechanism of action mimicking CDNF and to improve functional recovery of damaged neurons in preclinical models. Importantly, in an initial animal model, HER-096 has been shown to readily penetrate the blood brain barrier allowing for convenient subcutaneous dosing. Thanks to their multimodal mechanism of action, Herantis’ molecules have the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit https://www.herantis.com